Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic

1 Feb 2009

Abstract excerpt

B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in human adults of the Western world and no definitive cure is yet available. The disease is characterized by accumulation of clonal malignant B lymphocytes resistant to apoptosis. Strategies to hit the anti-apoptotic drift of the Bcl-2 family in B-CLL cells are being explored. A novel peptidomimetic based on the BH3 domain of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chronic Lymphocytic Leukemia Research
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19164937
DOI: 10.4161/cbt.8.3.7424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimeticPMID 19164937Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell MalignanciesSemantic proximity Read ↗

Mitochondrial apoptosis and BH3 mimeticsSemantic proximity Read ↗

Apoptosis inducers in chronic lymphocytic leukemiaSemantic proximity Read ↗

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancerSemantic proximity Read ↗

The BCL-2 arbiters of apoptosis and their growing role as cancer targetsSemantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatmentSemantic proximity Read ↗

Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profilingSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.